Exelon Approved To Treat Parkinson’s Dementia
Yesterday, the FDA approved Exelon (rivastigmine tartrate) made by Norvartis for the additional indication of mild to moderate dementia associated with Parkinson’s disease.
FDA OKs drug to treat Parkinson’s dementia - Yahoo! News
Exelon was originally approved in 2000 for mild to moderate dementia associated with Alzheimer’s dementia. It is the first drug to be approved to treat dementia associated with Parkinson’s disease.
It is not without side effects such as nausea and weight loss. Some also had a worsening of tremors associated with the drug.
I personally have been lucky and not had to deal with a family member or friend having either Parkinson’s or Alzheimer’s so I can’t say if I think the side effects are worth the potential risk. I do hope that this is a first step towards improving the condition of people with these diseases and that more advanced better treatments will be coming in future years.
Further resources:
- Alzheimer’s Disease Treatment - Exelon (rivastigmine tartrate)
- Exelon prescribing information (pdf)
- Exelon Online, Description, Chemistry, Ingredients - Rivastigmine Tartrate - RxList Monographs
- Yahoo! News Search Results for exelon drug
- exelon drug - Google News
Here is what the blogsphere is saying about Exelon:
Technorati Tags: dementia, Exelon, FDA, Novartis, Parkinson’s disease, rivastigmine
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
